Immune to Cancer: The CRI Blog
-
CRI-Funded Trial Reveals Promising Potential of Immunotherapy Combination in Metastatic Pancreatic Cancer
Interim data from a novel immunotherapy-chemotherapy combination that targets the CD40 and PD-1 pathways show promising anti-tumor…
-
AACR19 Preview: CRI Scientists Showcase the Future of Immunotherapy
The 2019 AACR annual meeting kicks off March 29 in Atlanta and will feature the work of…
-
Immunotherapy Combination Approved as First-Line Option for Patients with Advanced Triple-Negative Breast Cancer
Patients with advanced triple-negative breast cancer can now receive frontline treatment with immunotherapy in combination with chemotherapy.
-
How Immunotherapy Is Making an Impact in Liver Cancer
We spoke with Bruno Sangro, MD, PhD, about the current treatment landscape for patients with liver cancer,…
-
FDA Approves Pembrolizumab Immunotherapy for Advanced Liver Cancer
Patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer, can now receive PD-1…
-
CICON18 Day 3 Update: Targeting Tumor Mutations with Vaccine-Based Immunotherapies
The third day of CICON18 explored cutting-edge strategies to identify and target the mutated markers that distinguish…
-
Dr. James P. Allison, CRI Scientific Director, Awarded 2018 Nobel Prize along with Dr. Tasuku Honjo
Dr. Allison’s discoveries and determination led to the development of the first FDA-approved checkpoint immunotherapy
-
Cemiplimab Becomes First Treatment Approved for Advanced Cutaneous Squamous Cell Carcinoma
Immunotherapy is now approved for patients with advanced forms of the second most common form of skin…
-
Recapping the Third Annual Rational Combinations 360°
In September, experts across the immunology and immunotherapy spectrum convened in Philadelphia to discuss the latest advances…